Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider

Bibliographic Details
Title: Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider
Authors: Brittany A. Klein, Muhammad Ali Shazib, Alessandro Villa, Fábio de Abreu Alves, Piamkamon Vacharotayangul, Stephen Sonis, Stefano Fedele, Nathaniel S. Treister
Source: Frontiers in Oral Health, Vol 3 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Dentistry
Subject Terms: cancer, immunotherapy, oral medicine, oral pathology, toxicity, Dentistry, RK1-715
More Details: Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sjögren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxicities as part of the care team for patients treated with ICIs.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2673-4842
Relation: https://www.frontiersin.org/articles/10.3389/froh.2022.968157/full; https://doaj.org/toc/2673-4842
DOI: 10.3389/froh.2022.968157
Access URL: https://doaj.org/article/98124f89240c485dabe2eeb820041575
Accession Number: edsdoj.98124f89240c485dabe2eeb820041575
Database: Directory of Open Access Journals
More Details
ISSN:26734842
DOI:10.3389/froh.2022.968157
Published in:Frontiers in Oral Health
Language:English